N/A N=141 Renal Osteodystrophy: An Individual Management Approach
Kidney Failure, Chronic
Primary: Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip — -10.71; 5.72; -3.52; .2 g/cm^3 — p=.443
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
N/A N=55 Effects of Gastric Bypass Surgery and Calcium Metabolism and the Skeleton
Obesity, Morbid · Gastric Bypass
Primary: Change in Intestinal Calcium Absorption — -25.8 % of ingested calcium that is absorbed
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
N/A N=3 Calcium and Phosphorus Whole-Body Balance and Kinetics in Patients With Moderate Chronic Kidney Disease
Phosphorus and Calcium Disorders · Chronic Kidney Disease Mineral and Bone Disorder · Chronic Kidney Diseases
Primary: Fractional Calcium Absorption — 0.30; 0.42 fraction of 1.00
Phase 2 N=22 Metabolic Effects of Paricalcitol
Chronic Kidney Disease
Primary: Glucose Area Under the Curve (AUC) — 20817; 21139 mg*min/dL
Phase 1 N=19 Melatonin Osteoporosis Prevention Study
Osteoporosis · Osteopenia
Primary: The Effect of Melatonin (3 mg) or Placebo on the Mean Change in Serum Osteocalcin (OC) Levels in Women After 6 Months, as Compared to Baseline — -0.6; 1.83 ng/mL
Phase 2 N=241 Adding Phosphorus to Osteoporosis Drug Treatment
Osteoporosis · Osteopenia
Primary: Lumbar Spine and Hip BMD, Measured as Grams Per Square Centimeter. — 0.76; 0.78; 0.88; 0.86 g/cm2
Phase 2 N=10 Healthy Body, Healthy Bones After Bariatric Surgery Trial
Bariatric Surgery Candidate · Bone Loss · Bone Resorption
Primary: Change in Hip Bone Mineral Density (BMD) — 0; -.03 g/cm2
N/A N=12 Calcium and Phosphorus Balance and Calcium Kinetics in Patients With Stage 3/4 Chronic Kidney Disease
Chronic Kidney Disease
Primary: Calcium Balance — 61; 508 mg/d calcium
N/A N=22 Prevention of Post Operative Bone Loss in Children
Osteoporosis · Cerebral Palsy · Spina Bifida
Primary: Amount of Bone Density Lost (%) From pre-to Post-operative DXA Scan — 0.043; -0.025 percent change
N/A N=96 Effect of Diabetic Medications on Bone Metabolism
Osteoporosis · Type 2 Diabetes Mellitus
Primary: Changes in BMD at Femoral Neck — -3.2; 0.25 percentage of change in BMD — p=<0.05
Phase 3 N=78 Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Hematological Malignancies
Primary: Percentage Change in Bone Mineral Density From Baseline to 6 and 12 Months — 0.06; -2.61; -3.63; -4.85 Percentage change
Phase 2 N=244 Musculoskeletal Effects of Bicarbonate
Muscle Loss · Fractures · Osteoporosis, Age Related
Primary: The Dose of Potassium Bicarbonate Needed for Maximal Suppression of 24-hr Urinary N-telopeptide — 240; 230; 241; -53 nmol/day
Phase 2 N=61 Bone Mass and Strength After Kidney Transplantation
End Stage Renal Disease · Kidney Transplantation · Bone Loss
Primary: Percent Change in Bone Density From Pre to Post-calcitriol Treatment Compared to Placebo as Assessed by Both Standard Methodologies — -0.81; -0.70 percent change
Early Phase 1 N=92 CYP3A4 Activity and Mineral Homeostasis
Vitamin D and Calcium Homeostasis
Primary: 1, 25(OH) D3 Vitamin D — 3.2; 1.7; 3.7; -3.3 pM — p=0.884
Phase 4 N=83 The Effects of Potassium Citrate on Bone Metabolism
Bone Diseases, Metabolic · Osteoporosis, Postmenopausal
Primary: Urinary-N-telopeptide — 47.2; 51.6; 44.5; 47 nml BCE/nmol creatinine
N/A N=545 Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
N/A N=138 Bone Health in Pediatric Crohn's Disease: A Low Magnitude Mechanical Stimulus Trial
Crohn Disease
Primary: Change in Tibia Trabecular Volumetric Bone Mineral Density (BMD) Z-score at 12 Months — 0.15; 0.23 Z-score — p=0.38
N/A N=18 Enhancing Skeletal Adaptations to PTH and Exercise
Exercise · Bone Resorption · Bone Formation
Primary: Change in C-terminal Peptide of Type 1 Collagen (CTX) — 0.03; 0.03; 0.05; 0.03 ng/mL
N/A N=94 Bone Health in Facioscapulohumeral Muscular Dystrophy
Facioscapulohumeral Muscular Dystrophy
Primary: Bone Mineral Density in FSHD — -0.4 z-score
N/A N=93 Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism
Hyperthyroidism · Hypothyroidism
Primary: Thyroid Extreme CT — 0.89; 1.16 mm
Phase 2 N=23 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa
Anorexia Nervosa · Osteoporosis
Primary: Percent Change in Lumbar Spine Bone Mineral Density — 5.6; 0.2 percentage of change — p=< 0.01
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
Phase 3 N=515 A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)
Osteoporosis
Primary: Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26 — 8.6; 31.0 Percentage of Participants — p=<0.001
Phase 4 N=12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)
Osteoporosis · Bone Loss · Spinal Cord Injury
Primary: BMD at Left Total Hip — 0.02 % change in BMD (gm/cm2) from baseline
N/A N=9 Exercise Mode and Acute Bone Resorption
Osteoporosis · Aging
Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
Phase 2 N=22 Hydroxyproline Influence on Oxalate Metabolism
Hyperoxaluria
Primary: Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Oxalate (UOx) — 12.8; 32.9; 14.8 percent converted
N/A N=22 Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Osteoporosis
Primary: Change in Bone Mineral Density (BMD) in HIP at 6 Months — -0.041; 0.011 grams/cm^2
N/A N=180 Magnesium Treatment on Vitamin D Metabolism in Participants Completed Personalized Prevention of Colorectal Cancer Trial
Colorectal Cancer
Primary: Comparisons of the Changes of Blood 25-Hydroxyvitamin D3 (25(OH)D3) Between Magnesium Treatment and Placebo Arm, Stratified by the Baseline 25-hydroxyvitamin D (25(OH)D)…